Calidi Biotherapeutics Stock

www.calidibio.comHealthcare / BioTech & PharmaFounded: 2014

Calidi Biotherapeutics, founded in 2015, is a clinical-stage biotechnology company that strives to pioneer advancements in the field of oncolytic virus-based immunotherapies. The company's mission is to transform the cancer treatment landscape by unlocking the power of the immune system. Calidi Biotherapeutics' novel therapies aim to improve patient survival and quality of life by selectively killing cancer cells while activating immune responses. The company is headquartered in San Diego, California.

Register To Buy and Sell Shares

For more details on financing and valuation for Calidi Biotherapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Calidi Biotherapeutics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Calidi Biotherapeutics.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.

Calidi Biotherapeutics investors also invested in these private companies

Jackson Investment Group


Management Team

Allan Camaisa
Co-Founder, Chairman & Chief Executive Officer
Boris Minev
President, Medical and Scientific Affairs & Interim Chief Medical Officer
Tony Kalajian
Chief Accounting Officer & Interim Chief Financial Officer
Stephen Thesing
Chief Business Officer
Wendy Pizarro JD
Chief Legal Officer, Corporate Secretary, Chief Administrative Officer & Chief Diversity Officer
Scott Leftwich
Co-Founder & Vice Chairman

Frequently Asked Questions About Calidi Biotherapeutics’ Stock

Can you buy Calidi Biotherapeutics’ stock?
Calidi Biotherapeutics is not publicly traded on NYSE or NASDAQ in the U.S. To buy Calidi Biotherapeutics’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
Can you sell Calidi Biotherapeutics’ stock?
Yes, you can sell stock of a private company like Calidi Biotherapeutics. Forge can help you sell your Calidi Biotherapeutics stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
What is Calidi Biotherapeutics’ stock price?
Calidi Biotherapeutics is a privately held company and therefore does not have a public stock price. However, you may access Calidi Biotherapeutics’ private market stock price with Forge Data.
What is Calidi Biotherapeutics’ stock ticker symbol?
Calidi Biotherapeutics does not have an official ticker symbol because this company is not currently publicly traded.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Calidi Biotherapeutics Announces Commitment of $25 Million in Series B Funding to Advance Stem Cell-Based Platforms for the Delivery and Potentiation of Oncolytic Viruses to Treat Cancer
Calidi Biotherapeutics, Inc. (“Calidi”), a clinical-stage biotechnology company that is pioneering the development of allogeneic cell-based delivery of oncolytic viruses, today announced the commitment of $25 million in Series B funding led by Jackson Investment Group (“JIG”), who has funded an initial investment of $5 million, and participation from Calidi Cure, LLC, a consortium of new and existing investors led by Allan Camaisa, CEO and Chairman of Calidi.
Updated on: May 26, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.